Q2 FY2026 EarningsQ2 FY2026 results outperformed consensus on profitability metrics, reporting a narrower-than-expected net loss of $43.1M vs. the $44.6M anticipated. Diluted GAAP EPS of -$0.23 beat the consensus mean of -$0.24, driven by disciplined cost management as R&D and G&A expenses fell 24% and 16% YoY, respectively. With $116.8M in cash, management extended the runway guidance into Q3 2027, alleviating near-term liquidity concerns while clinical milestones for NMRA-511 and NMRA-898 remain on track for H2 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Neumora Therapeutics(NMRA) the EBIT is -42.19 M (+21.93%), Beat estimate;the EPS is -0.23 (+30.3%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.04B21.93%
-0.04B18.56%
+0.00B3.37%
EPSExceed expectations
-0.2330.30%
-0.240827.04%
+0.01083.26%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf